The COVID-19 pandemic brought lipid nanoparticles (LNPs) to prominence, with multiple pharmaceutical manufacturers – including Moderna and Pfizer-BioNTech – rapidly developing mRNA-LNP vaccines that were administered globally. The success of these vaccines has firmly established the potential of this technology to help treat a broad scope of diseases and illnesses, especially using gene therapy approaches, where LNPs are already demonstrating promise as non-viral delivery vectors. How